New biomarkers for lung cancer

Paci, Massimiliano; Rapicetta, Cristian; Maramotti, Sally

doi:10.1517/17530051003725113

Cited by 10 publications

(6 citation statements)

References 222 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Carcinoma embryonic antigen (CEA) is one of the currently available biomarkers for lung adenocarcinoma. It has been reported that the sensitivity and specificity of CEA are 69% and 68%, respectively [26]. Similar levels of specificity and sensitivity were achieved for PGE-MUM.…”

Section: Discussionsupporting

confidence: 67%

Prostaglandin E-Major Urinary Metabolite (PGE-MUM) as a Tumor Marker for Lung Adenocarcinoma

Kawamoto

Hara

Araya

et al. 2019

Cancers

View full text Add to dashboard Cite

Background: Prostaglandin E2 (PGE2) is metabolized to prostaglandin E-major urinary metabolite (PGE-MUM). Enhanced cyclooxygenase-2 (COX-2) expression demonstrated in lung adenocarcinoma indicates increased PGE-MUM levels in patients with lung adenocarcinoma. Objectives: We aimed to elucidate the clinical usefulness of measuring PGE-MUM as an indicator of tumor burden in patients with lung adenocarcinoma. Methods: PGE-MUM was measured by a radioimmunoassay in control healthy volunteers (n = 124) and patients with lung adenocarcinoma (n = 54). Associations between PGE-MUM levels and clinical characteristics of the patients (including lung cancer stage and TNM factors (T: Tumor, N: Node, M: Metastasis) were examined. Results: PGE-MUM levels were significantly elevated in patients with lung adenocarcinoma. A PGE-MUM level of 14.9 μg/g∙Cr showed 70.4% sensitivity and 67.7% specificity for the diagnosis of lung adenocarcinoma. PGE-MUM levels tended to be positively correlated with cancer progression as determined by the TNM staging system. Advanced stage (stage III, stage IV, and recurrence) was significantly associated with high PGE-MUM levels by logistic regression analysis. No apparent correlation was demonstrated between PGE-MUM and carcinoma embryonic antigen (CEA) levels. Conclusions: PGE-MUM can be a promising biomarker reflecting the systemic tumor burden of lung adenocarcinoma.

show abstract

Section: Discussionsupporting

confidence: 67%

Prostaglandin E-Major Urinary Metabolite (PGE-MUM) as a Tumor Marker for Lung Adenocarcinoma

Kawamoto

Hara

Araya

et al. 2019

Cancers

View full text Add to dashboard Cite

show abstract

“…The online literature database PubMed was used to identify lung cancer miRNA expression profiling studies published from January 2003 until May 2014 (last accessed on 15 May 2014), by means of the 'Medical Subject Heading' terms: 'NSCLC' and 'microRNAs' in combination with the keywords 'profiling' and 'humans'. The results of previous studies to identify circulating miRNAs specific to lung cancer were inconsistent (24)(25)(26)(27), and potential biomarkers remain to be elucidated and exploited. Based on these previous findings, a list of 15 miRNAs was compiled, whose expression has already been reported as deregulated in cancer, or has not been investigated (Table III).…”

Section: Methodsmentioning

confidence: 99%

Role of deregulated microRNAs in non-small cell lung cancer progression using fresh-frozen and formalin-fixed, paraffin-embedded samples

et al. 2015

View full text Add to dashboard Cite

Abstract. Non-small cell lung cancer (NSCLC) is responsible for the highest number of cancer-associated mortalities worldwide, and the five-year survival rate is <15% following the initial diagnosis. MicroRNAs (miRNAs) serve important functions in a number of human diseases, including cancer. The present study investigated the expression status, clinical relevance and functional role of miRNA in NSCLC. miRNA expression profiling was performed in lung adenocarcinoma and adjacent unaffected lung tissues using 47 groups of fresh-frozen (FF) and 45 of formalin-fixed, paraffin-embedded (FFPE) samples from 11 pulmonary bulla. miR-21, -30e, -363 and -623 were further examined for differential expression in two independent cohorts. Other miRNAs, including miR-5100 and miR-650, were upregulated, while miR-10a and -26b were downregulated in FF NSCLC tissues. The associations between these miRNAs and their clinicopathological features were also investigated. miR-363, -10a and -145 were associated with lymph node status (P= 0.002, 0.005 and 0.007, respectively) and miR-650 and -145 were associated with differentiation (P=0.01 and 0.05, respectively). No associations were identified for the other miRNAs examined. In the FFPE NSCLC samples, miR-30e-5p correlated with the differentiation of the tissue (P= 0.011). The present study indicates that these miRNAs may be appropriate candidates for molecular diagnostic and prognostic markers in NSCLC.

show abstract

“…However, in practice, this system often fails in providing sufficient sensitivity and information of value for optimal screening. For example, for the diagnosis of lung cancer, CEACAM sensitivity and specificity is 69% and 68% respectively, while that for CYFRA 21-1 was 43% and 89%, respectively [ 27 ]. Diagnostic sensitivity of plasma ProGRP in distinguishing SCLC was estimated to be approximately 84%, and specificity 95% [ 28 ].…”

Section: Circulating Biomarkers Of Carcinogenesismentioning

confidence: 99%

Current and Prospective Protein Biomarkers of Lung Cancer

Zamay

Kolovskaya

et al. 2017

Cancers

146

View full text Add to dashboard Cite

Lung cancer is a malignant lung tumor with various histological variants that arise from different cell types, such as bronchial epithelium, bronchioles, alveoli, or bronchial mucous glands. The clinical course and treatment efficacy of lung cancer depends on the histological variant of the tumor. Therefore, accurate identification of the histological type of cancer and respective protein biomarkers is crucial for adequate therapy. Due to the great diversity in the molecular-biological features of lung cancer histological types, detection is impossible without knowledge of the nature and origin of malignant cells, which release certain protein biomarkers into the bloodstream. To date, different panels of biomarkers are used for screening. Unfortunately, a uniform serum biomarker composition capable of distinguishing lung cancer types is yet to be discovered. As such, histological analyses of tumor biopsies and immunohistochemistry are the most frequently used methods for establishing correct diagnoses. Here, we discuss the recent advances in conventional and prospective aptamer based strategies for biomarker discovery. Aptamers like artificial antibodies can serve as molecular recognition elements for isolation detection and search of novel tumor-associated markers. Here we will describe how these small synthetic single stranded oligonucleotides can be used for lung cancer biomarker discovery and utilized for accurate diagnosis and targeted therapy. Furthermore, we describe the most frequently used in-clinic and novel lung cancer biomarkers, which suggest to have the ability of differentiating between histological types of lung cancer and defining metastasis rate.

show abstract

New biomarkers for lung cancer

Cited by 10 publications

References 222 publications

Prostaglandin E-Major Urinary Metabolite (PGE-MUM) as a Tumor Marker for Lung Adenocarcinoma

Prostaglandin E-Major Urinary Metabolite (PGE-MUM) as a Tumor Marker for Lung Adenocarcinoma

Role of deregulated microRNAs in non-small cell lung cancer progression using fresh-frozen and formalin-fixed, paraffin-embedded samples

Current and Prospective Protein Biomarkers of Lung Cancer

Contact Info

Product

Resources

About